Suven Pharmaceuticals Ltd

BSE
SUVENPHAR •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or open an account for live prices.
Start SIP in Suven Pharmaceuticals Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
Near 52W High of ₹889.70
36.4
TTM PE Ratio
High in industry
74.6
Price to Book Ratio
High in industry
10.9
Dividend yield 1yr %
0
TTM PEG Ratio
PEG TTM is negative
-2.8
RSI
RSI is mid-range
65.2
MFI
MFI is mid-range
66.3

Suven Pharmaceuticals Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Suven Pharmaceuticals Ltd shareholding Pattern

Promoter
50.1%
Foreign Institutions
9.8%
Mutual Funds
14.8%
Domestic Institutions
17.4%
Public
22.7%
Promoter
50.1%
Foreign Institutions
9.5%
Mutual Funds
15.3%
Domestic Institutions
17.2%
Public
23.1%
Promoter
60%
Foreign Institutions
10.1%
Mutual Funds
13.4%
Domestic Institutions
16%
Public
13.9%
Promoter
60%
Foreign Institutions
10%
Mutual Funds
12.2%
Domestic Institutions
14.1%
Public
15.8%
Promoter
60%
Foreign Institutions
9.5%
Mutual Funds
9.1%
Domestic Institutions
10.6%
Public
19.9%
Promoter
60%
Foreign Institutions
9.5%
Mutual Funds
8.6%
Domestic Institutions
11.4%
Public
19.1%

Suven Pharmaceuticals Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
16
Bearish Moving Averages
0
5Day EMA
851.70
10Day EMA
841.40
12Day EMA
836.30
20Day EMA
814.00
26Day EMA
798.10
50Day EMA
753.10
100Day EMA
709.70
200Day EMA
662.90
5Day SMA
853.20
10Day SMA
844.20
20Day SMA
819.50
30Day SMA
781.00
50Day SMA
723.30
100Day SMA
686.60
150Day SMA
686.20
200Day SMA
664.90
Delivery & Volume
Resistance & Support
861.40
Pivot
Resistance
First Resistance
887.70
Second Resistance
908.30
Third Resistance
934.60
Support
First Support
840.80
Second support
814.50
Third Support
793.90
Relative Strength Index
65.24
Money Flow Index
66.26
MACD
38.28
MACD Signal
39.94
Average True Range
35.22
Average Directional Index
41.90
Rate of Change (21)
21.46
Rate of Change (125)
27.37
Peer comparison
Compare
Company
Market Price
Market Cap
52W Low
52W High
Alembic Pharmaceuticals Ltd.
21339.88
682
1192.75
AstraZeneca Pharma India Ltd.
17661.63
3730
7550
Natco Pharma Ltd.
22571.43
725
1325.4
Sanofi India Ltd.
14722.04
5850.55
10526.05
Laurus Labs Ltd.
23189.24
328.15
484.95
Piramal Pharma Ltd.
20714.81
87.55
167.95

Suven Pharmaceuticals Ltd Company background

Founded in: 2018
Managing director: Venkatanaga Kali Vara Prasad Raju Vetukuri
Suven Pharmaceuticals Limited (SPL) is a biopharmaceutical company, incorporated on 6th November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors. Its services include custom synthesis, process RD, scaleup and contract manufacturing of intermediates, APIs and formulations. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.During the year 201920, Suven Life Sciences Ltd. (SLSL) has transferred the CRAMS business undertaking to the Company in accordance with the Scheme of Arrangement (Demerger) approved by the Honble NCLT, Hyderabad Bench now integrated with Contract Development and Manufacturing Operations (CDMO) business model of the Company. In terms of the sanctioned Scheme, the Company issued and allotted 1 (One) fully paid up equity share of face value of Re 1/ (Rupee One only) each of SPL for every 1 (One) fully paid up equity share of face value of Re 1/ (Rupee One only) each held by each shareholder in the Demerged Company (SLSL) as on the Record Date (i.e., 22nd January, 2020), thereby resulted in a mirror shareholding of SLSL in the Company. The equity shares of the Company were listed to trade w.e.f. 09th March, 2020.The Board of Directors in its meeting held on August 17, 2020 considered, approved and recommended an issue of bonus shares in the proportion of (1:1) one new equity share of the Company of Re 1 each for every one existing equity share of the Company of Re 1 each.The company has a massive Rs 320crore capex plan. Suven has invested Rs 120 crore in 201920. The balance is to be invested in 202021.During the year 201920, the Company invested USD35 million in Rising Pharma Holdings, Inc., USA through its wholly owned subsidiary, Suven Pharma, Inc., USA. Suven Pharma, Inc., in USA was originally formed by Suven Life Sciences Ltd while pursuing various business opportunities in CRAMS business undertaking during the demerger transition period now integrated with CDMO business of the Company, as per the decisions taken by the Board of the Company and of the Demerged Company i.e., Suven Life Sciences Ltd, in accordance with the enabling provisions of Scheme of Arrangement as sanctioned by Honble NCLT Hyderabad Bench. As a result, Suven Pharma, Inc., in USA has become wholly owned subsidiary of the company during the FY 20192020.As on 31 March 2020,the company has one subsidiary and one associate company under its roof.The company filed 11 ANDAs as on March 31, 2020 and three of those secured the green light from the regulator.The Board has allotted the Bonus shares at 1:1 ratio in its Board Meeting held on 29 September 2020. Accordingly the number of shares increased from 12,72,82,478 to 25,45,64,956..In 2022, the Company filed 17 ANDAs of which 9 had received approvals and 8 products were launched up to March, 2022.During year 2022, Company acquired 100% stake in Casper Pharma Private Limited, a Hyderabad based SEZ unit and Casper Pharma became a Wholly Owned Subsidiary of the company.
Read More

Suven Pharmaceuticals Ltd FAQs

The past 1-year return of Suven Pharmaceuticals Ltd [SUVENPHAR] share was 82.1. The Suven Pharmaceuticals Ltd [SUVENPHAR] share hit a 1-year low of Rs. 471 and a 1-year high of Rs. 889.

The Mutual Fund Shareholding was 14.78% at the end of .

You can easily buy Suven Pharmaceuticals Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -